Theravance Biopharma (TBPH) Financial Statements & Analysis

Theravance Biopharma (TBPH) Income Statement

Theravance Biopharma reported revenue of $107.46M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 66.9% from $64.38M a year earlier. Net income was $105.89M, a net margin of 98.5%. Gross margin was 94.9% and operating margin -12.3%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $20.73M, down 20.9% from the same quarter a year earlier.

Theravance Biopharma Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Theravance Biopharma, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	107.46	64.38	57.42	51.35	55.31	71.86	73.41	60.37	15.39
Cost of Revenue	5.52	37.64	40.62	63.39	193.66	0.00	0.00	0.72	6.03
Gross Profit	101.95	26.74	57.42	-12.05	-138.35	71.86	73.41	59.66	9.36
Operating Expenses
Research & Development	37.41	38.05	40.62	63.39	193.66	260.95	219.25	201.35	173.89
Selling, General & Administrative	73.65	69.17	70.10	67.07	99.30	108.53	106.08	97.06	95.59
Operating Expenses	115.20	73.69	113.46	130.47	292.95	369.48	325.33	298.41	269.48
Operating Income	-13.25	-46.95	-56.04	-79.12	-237.64	-297.63	-251.92	-238.75	-260.12
Other Income/Expense
Interest Income	0.00	4.88	9.02	8.55	1.11	4.44	8.40	11.97	4.79
Interest Expense	2.46	2.55	-2.35	6.37	8.55	8.55	31.86	10.48	8.55
Other Income/Expense	142.49	2.34	6.77	-15.87	-20.14	-5.72	10.24	12.67	-11.59
Income
Income Before Tax	129.25	-44.61	-49.27	-92.82	-265.22	-303.34	-241.68	-226.09	-271.71
Income Tax Expense	23.35	11.80	5.92	0.01	-0.15	-8.52	-5.22	-10.56	13.69
Net Income	105.90	-56.42	-55.19	872.13	-199.43	-278.02	-236.46	-215.52	-285.41
Net Income - Continuous Operations	105.90	-56.42	-55.19	-92.82	-265.07	-278.02	-236.46	-215.52	-285.41
Net Income - Discontinued Operations	-	-	-	964.96	65.65	-	-	-	-
EBITDA	137.22	-38.45	-51.65	-79.42	-248.08	-287.82	-203.60	-212.44	-259.14
EBIT	-3.60	-42.07	-53.65	-86.45	-256.68	-297.63	-	-	-
Depreciation & Amortization	5.52	3.62	2.00	7.02	8.60	6.97	6.21	3.17	4.03
Earnings Per Share
Basic EPS	2.00	-1.00	-1.00	12.00	-3.00	-4.00	-4.00	-4.00	-5.00
Diluted EPS	2.00	-1.00	-1.00	12.00	-3.00	-4.00	-4.00	-4.00	-5.00
Basic Shares Outstanding	50.32	48.85	55.30	73.59	69.46	62.35	55.61	53.97	52.35
Diluted Shares Outstanding	51.51	48.85	55.30	73.59	69.46	62.35	55.61	53.97	52.35

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Theravance Biopharma Financial Statements

What was Theravance Biopharma's revenue in fiscal 2025?

Theravance Biopharma reported revenue of $107.46M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 66.9% from $64.38M a year earlier.

Is Theravance Biopharma profitable?

Yes. Theravance Biopharma earned net income of $105.89M in fiscal 2025, a net margin of 98.5%. In fiscal 2024 it lost $56.42M.

What is Theravance Biopharma's operating margin?

Theravance Biopharma's operating income was −$13.25M on revenue of $107.46M in fiscal 2025, an operating margin of -12.3%, compared with -72.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition